Background
==========

As adequate auditory stimulation in early childhood is fundamental for optimal speech and language development as well as for the acquisition of literacy skills, early hearing detection and interventions for deaf children are essential \[[@B1],[@B2]\]. A failure to undertake early hearing detection and intervention within the first year of life for permanent congenital and early-onset hearing impairment (PCEHI) might lead to severe and irreversible impairment in language acquisition and speech development in early life and poor educational and occupational performance in adulthood \[[@B3]-[@B7]\]. However, compared to those major disease set out in the Millennium Development Goals, PCEHI, as a non-fatal but life-long disease, has been neglected particularly in developing countries \[[@B8]-[@B10]\].

Neonatal hearing screening (NHS) program has made a rapid development in recent years. The benefit of NHS is that it allows most PCEHI to be detected early enough for optimal intervention \[[@B11],[@B12]\]. NHS has been routinely offered as a vital component of early childhood care in developed countries, whereas such a screening program is still at the pilot or preliminary stage as regards its nationwide implementation in developing countries where hearing care services, such as the provision of hearing aids, only cover approximately 1% of all the population \[[@B13]\].

Cost-effectiveness analysis (CEA) has been used as a tool to prioritize scarce health resources, which allows the comparison of various intervention options \[[@B14],[@B15]\]. Although CEA is currently the cornerstone of health investment, it might be the only one approach implemented in the developing countries in Africa and Asia to evaluate selected interventions for hearing impairment \[[@B16]\]. The prospects of any immediate action to implement NHS programs are still uncertain in most of developing countries, since the current approach to global disease prioritization and health resource allocation requires vital data in an environment where funds to invest are always scarce.

In China, the largest developing country in the world, the Ministry of Health has recently decided to address the issue of non-fatal congenital diseases in neonatal health care which have until now been neglected but have a considerable impact on the individual, family and society. There is now a political commitment to scale-up a hospital-based neonatal hearing screening program, which will include expanded screening, diagnosis and intervention services \[[@B17]\]. A key policy question on how to implement the program under a system of decentralized health financing and authority at the provincial level has been raised. Therefore, this study aims to determine cost-effectiveness of the NHS program implementation, in case of eight provinces of China, in order to support evidence-based national policy making in China.

Methods
=======

Cost-effectiveness model
------------------------

In the present study, we modeled the cost-effectiveness of two screening programs: universal screening which covers all live births, and targeted screening which targets those with one or more risk factors (Figure [1](#F1){ref-type="fig"}). Universal NHS detects infants with the disorder who have no known risk factors associated with PCEHI, which accounts for approximately 50% of PCEHI cases \[[@B18],[@B19]\]. The targeted screening of newborns with risk factors for hearing impairment is one alternative to universal NHS. Although the universal strategy has been widely recommended as it can detect more cases, recently Joint Committee on Infant Hearing (JCIH) suggested that targeted screening might be more appropriate for developing countries because of cost considerations \[[@B20]\].

![**The tree model for cost-effectiveness of two screening strategies (universal screening and targeted screening)**.](1472-6963-12-97-1){#F1}

A natural history model of all infants with and without hearing impairments was developed to characterize the process of screening, diagnosis and interventions through all possible stages. All neonates annually born in eight provinces (Beijing, Shandong, Hebei, Henan, Jiangxi, Guangxi, Guangdong, and Zhejiang) of China from 2007 to 2009 were simulated (Figure [2](#F2){ref-type="fig"}). In these 8 provinces of China, Beijing, Shandong, Hebei, Guangdong, and Zhejiang are relatively developed provinces, whereas Henan, Jiangxi, and Guangxi are relatively developing provinces. The model determined the proportion of infants with PCEHI in the simulated cohort who would potentially benefited from the NHS program, where detection by a process of screening and diagnosis occurs before 6 months and intervention before 12 months.

![**The map of study sites including Beijing (☆), Shandong, Hebei, Henan, Jiangxi, Zhejiang, Guangxi and Guangdong**.](1472-6963-12-97-2){#F2}

Probability parameters
----------------------

Depending on the program coverage and screening strategies, neonates could either receive or not receive screening. Neonates screened consisted of false-positive and false-negative cases, and those with a positive result are referred to the diagnosis center. With the probability of drop-out from the diagnosis center and an inaccessibility of interventions, referred neonates might not be either diagnosed or receive interventions. In the final instance, infants with the disorder would have treated or untreated health outcomes, depending on whether they received screening, diagnosis and interventions.

In this model, probability parameters potentially affecting cost-effectiveness are the proportion of infants with one or more high risks, the prevalence of PCEHI in the general population and high-risk population, the sensitivity, specificity, and coverage of the screening program which shows neonates screened among those targeted by the screening program (general population or high-risk population), diagnosis rate which shows those diagnosed before 6 months among those referred after the screening, and intervention rate which shows infants fitted with hearing aids or cochlear implants and that have started the rehabilitation course before 12 months of age among those with the disorder as detected by the diagnosis process (Table [1](#T1){ref-type="table"}). The coverage, diagnosis rate and intervention rate were calculated based on data in the newly established database in the study sites, while others were acquired from literature review.

###### 

Parameter values and plausible ranges for probability variables used in the baseline and sensitivity analysis

  ----------------------------------------------------------------------------------------------
  Items                             Baseline   Range for sensitivity analysis   References
  --------------------------------- ---------- -------------------------------- ----------------
  High-risk infants                 7%         6-8%                             \[[@B21]\]

                                                                                

  Prevalence in all live-born       0.30%      0.2-0.4%                         \[[@B22]\]\
                                                                                \[[@B23]\]\
                                                                                \[[@B24]\]\
                                                                                \[[@B25]\]\
                                                                                \[[@B26]\]

                                                                                

  Prevalence in high risk infants   3.00%      1.15-3.59%                       \[[@B27]\]\
                                                                                \[[@B28]\]\
                                                                                \[[@B29]\]\
                                                                                \[[@B30]\]\
                                                                                \[[@B31]\]\
                                                                                \[[@B32]\]

                                                                                

  Sensitivity                       95%        90-100%                          \[[@B17]\]\
                                                                                \[[@B32]\]\
                                                                                \[[@B33]\]

                                                                                

  Specificity                       95%        90-100%                          \[[@B18]\]\
                                                                                \[[@B34]\]\
                                                                                \[[@B35]\]

                                                                                

  Coverage                          60%        15-99%                           \[[@B36]\]\
                                                                                (Primary data)

                                                                                

  Diagnosis rate                    50%        20-95%                           \[[@B36]\]\
                                                                                (Primary data)

                                                                                

  Intervention rate                 50%        10-95%                           \[[@B36]\]\
                                                                                (Primary data)
  ----------------------------------------------------------------------------------------------

Costs for the program implementation
------------------------------------

We followed the guideline developed by the World Health Organization (WHO) \[[@B37]\] to estimate costs for the program implementation. These included capital costs (*e.g.*office buildings, furniture and equipment), recurrent costs such as the salaries of the personnel, materials and supplies, utilities, equipment maintenance, database management, training and transport, and patient-level costs which were composed of the registration fee, screening tests, diagnosis tests, drugs, treatment with a hearing aid, treatment with a cochlear implant, rehabilitation courses, and transportation charges for diagnostic procedures and treatments. The capital investments of office buildings, furniture and equipment were annualized by depreciation, for which the life spans were standardized by Ministry of Finance of the People\'s Republic of China and Ministry of Health of the People\'s Republic of China \[[@B38]\] Table [2](#T2){ref-type="table"} summarized cost estimates for cost-effectiveness analysis. Data for the cost estimates came from the annual financial report of screening facilities, diagnosis centers and rehabilitation facilities in the surveyed provinces, with the cooperation of experts in hospital accounting. Costs were first calculated in RMB, the Chinese currency, with the costs across different years being adjusted in accordance with the price level in 2009 based on the GDP deflator. They were then converted into international dollars (Int\$), by dividing Purchasing Power Parities \[[@B39]\].

###### 

Parameter values and plausible ranges for cost estimates per case used in the baseline and sensitivity analysis (Int \$)

  Items              Hearing screening method   Baseline      Ranges for sensitivity analysis   
  ------------------ -------------------------- ------------- --------------------------------- -------------
  Screening                                                                                     
                                                                                                
   Program costs                                                                                
                                                                                                
   Capital costs     OAE                        240,813,700   170,712,610                       307,291,540
                                                                                                
                     OAE+AABR                   429,951,870   322,027,570                       559,461,040
                                                                                                
   Recurrent costs   OAE                        150           100                               200
                                                                                                
                     OAE+AABR                   230           130                               360
                                                                                                
   Patient costs                                30            10                                50
                                                                                                
  Diagnosis                                                                                     
                                                                                                
   Program costs                                                                                
                                                                                                
   Capital costs                                15,950,600    11,014,773                        21,467,600
                                                                                                
   Recurrent costs                              240           130                               360
                                                                                                
   Patient costs                                170           90                                310
                                                                                                
  Intervention                                                                                  
                                                                                                
   Program costs                                                                                
                                                                                                
   Capital costs                                13,829,240    12,430,260                        15,554,540
                                                                                                
   Recurrent costs                              290           200                               440
                                                                                                
   Patient costs                                22,690        18,860                            29,140

Abbreviation: Otoacoustic emission (OAE); Automated auditory brainstem response (AABR)

Apart from the costs of program implementation for estimates of cost-effectiveness, it is reasonable to assume (and thus estimate) that money would be saved if early detection and intervention was given. Early detection and intervention may bring expenditure on special education and rehabilitation reduction, social and medical services support decrease and incomes increase. However, there was no report on the long-term costs of the disorder from the published literature in China. In our model, we preliminarily attempted to estimate the potential long-term costs saving from the use of the NHS program, including medical services, special education and rehabilitation. It was assumed that improved language outcomes would result in a 10% decrease in special education costs and a 75% decrease in vocational rehabilitation costs \[[@B40],[@B41]\]. It was estimated based on data from hospitals, disabled people\'s federations \[[@B42]\] the provincial health agency and the provincial education agency. Table [3](#T3){ref-type="table"} presented a summary of the long-term costs saving.

###### 

Summary of estimates for long-term costs saving

  -----------------------------------------------------------------------------------------
  Items                                long-term costs saving (Int \$)   
  ------------------------------------ --------------------------------- ------------------
  Medical services                                                       

                                                                         

   For cases to fit hearing aid        1,960\                            1,960\
                                       (1,740-2,180)                     (1,740-2,180)

                                                                         

   For cases to fit cochlear implant   40,000\                           40,000\
                                       (38,000-42,500)                   (38,000-42,500)

                                                                         

  Special education\                   42,300\                           38,070\
  (9 years compulsory education)       (40,500-45,900)                   (36,450-41,310)

                                                                         

  Rehabilitation\                      82,400\                           20,600\
  (Up to 15 years)                     (75,200-88,400)                   (18,800-22,100)

                                                                         

  Total                                166,660\                          100,630\
                                       (155,440-178,980)                 (60,790-108,090)
  -----------------------------------------------------------------------------------------

Data collection
---------------

Data collection in the field included two components: costs related to the screening program which were acquired from general hospitals and maternal and child health hospitals providing screening and diagnosis services, and rehabilitation facilities, and transition probability parameters including the coverage of screening program, the diagnosis rate and intervention rate which were calculated based on data from the database established at the provincial level. A multiple of three parameters shows the proportion of infants with PCEHI potentially benefiting from the screening program among the targeted population (all or high-risk infants), in this study, calculated as the proportion of the benefit population \[[@B43]\].

After permission to use the database by the district health agencies, the data of the province were acquired. For the costs estimate, all facilities providing screening, diagnosis, and rehabilitation services were visited in selected districts and the annual financial report was analyzed by an expert in hospital accounting.

Estimates of health effects
---------------------------

In this study, population health is expressed as the number of Disability-Adjusted Life Years (DALYs) averted as a result of the screening program. DALYs lost due to PCEHI were calculated as the sum of Years Lost due to Disability (YLDs), as it is a non-fatal disorder, and the time period is life-long. Disability weights for adult-onset hearing impairment were adopted in the estimation, 0.216 for untreated disorders and 0.168 for treated disorders, respectively \[[@B44]\]. This was done because there was no evaluation for infants and children, and lifetime coverage rather than childhood coverage was thought to be able to minimize the discrepancy in the long term.

Cost-effectiveness analysis
---------------------------

The cost-effectiveness of a given intervention is typically expressed as costs per unit of effectiveness, with costs measured in monetary terms and effectiveness measured in health metrics terms. In this study, the average cost-effectiveness ratio (ACER) is calculated for each screening strategy by determining the cost for the program\'s implementation (except long-term costs saving) and total health effects in terms of DALYs averted. Incremental cost-effectiveness ratio (ICER) shows the absolute value of resources necessary to move to the next option. We calculated ICER for different screening strategies by dividing the incremental costs by the incremental health effects, in order to determine the priority of purchasing these services at different budgetary levels.

A multivariate sensitivity analysis was performed to determine uncertainty in health effect estimates and cost-effectiveness ratios, using a probabilistic modeling technique, known as Monte Carlo simulation. The simulation associating the estimates of costs and health effects as described above with each of the transition probability parameters was performed on one parameter at a time allowing for the input of extreme values while keeping the other parameters fixed at the their baseline level. The model was evaluated on 1,000 trials. It showed that any variation in the input parameter might result in a change of preference of strategies compared to the baseline result.

Results
=======

Benefit population of the current neonatal hearing screening program
--------------------------------------------------------------------

Demographic and socioeconomic information and the indicators of the program implementation including coverage rate, diagnosis rate and intervention rate in the six provinces were presented in Table [4](#T4){ref-type="table"}. The three variables (coverage rate, diagnosis rate and intervention rate) determined the total number of deaf infants finally receiving early interventions and benefiting from the screening program. The benefit population referred to the proportion of infants with the disorder who finally received beneficial early hearing detection and intervention. There was a huge disparity in this figure between different provinces. In general, these figures in the developed eastern provinces were much higher.

###### 

Basic information of study sites

  Provinces                             Beijing      Shandong     Hebei        Zhejiang     Guangdong    Henan                  Jiangxi                Guangxi
  ------------------------------------- ------------ ------------ ------------ ------------ ------------ ---------------------- ---------------------- ----------------
  Population^a^                         16,330,000   93,670,000   69,430,000   50,600,000   94,490,000   93,600,000             4,368,000              47,680,000
  Birth rate (per 1,000)^a^             8.32         11.11        13.33        11.26        11.96        11.26                  13.86                  14.19
  No. of live births per year^a^        135,866      1,040,674    925,502      1,053,936    1,130,100    1,053,936              605,405                676,579
  GDP per capita (Int\$)^b^             16,644.25    7,951.80     5,684.11     10,698.20    9,479.99     4,578.86               3,612.58               3,590.28
  Life expectancy^a^                    76.1         73.92        72.54        74.7         73.27        71.54                  68.95                  71.29
  Development status^c^                 Developed    Developed    Developed    Developed    Developed    Moderately developed   Moderately developed   Less developed
  No. of screening facilities^a^        548          1,402        1,296        722          1,154        1,341                  602                    553
  No. of diagnosis centers^a^           6            17           11           11           21           17                     11                     14
  No. of rehabilitation facilities^a^   12           14           8            8            15           10                     6                      5
  Coverage rate^d^                      97.8%        83.3%        91.3%        83.3%        97.0%        24.5%                  30.5%                  50.2%
  Diagnosis rate^d^                     97.4%        68.3%        60.0%        60.0%        75.0%        30.2%                  48.2%                  21.4%
  Intervention rate^d^                  77.1%        72.5%        76.1%        70.0%        75.0%        23.8%                  33.3%                  23.9%
  Proportion of benefit population      73.4%        41.3%        41.7%        35.0%        54.6%        1.8%                   4.9%                   2.6%

Data source:

^a^: Ministry of Health of the People\'s Republic of China \[[@B17]\].

^b^: International Monetary Fund \[[@B39]\].

^c^: Ministry of Health of the People\'s Republic of China \[[@B35]\].

^d^: Provincial data

Cost-effectiveness of different strategies in eight provinces
-------------------------------------------------------------

Table [5](#T5){ref-type="table"} shows implementation costs, DALYs averted, and cost-effectiveness of different NHS strategies in eight provinces. Based on GDP per capita in each province and baseline of transition probability parameters, universal strategy shows cost-effectiveness in Guangdong, Shandong, and Beijing, and targeted strategy shows cost-effectiveness in Zhejiang and Hebei, while neither of the screening strategy shows cost-effectiveness in Guangxi, Jiangxi and Henan.

###### 

Implementation costs, health effects and cost-effectiveness of different NHS strategies in eight provinces

  Items                                Guangxi      Jiangxi      Henan       Guangdong    Zhejiang     Hebei        Shandong     Beijing
  ------------------------------------ ------------ ------------ ----------- ------------ ------------ ------------ ------------ -----------
  Total costs (Int \$)                                                                                                           
   Universal strategy                  10,498,335   23,063,105   9,121,907   39,077,961   17,144,588   33,472,076   32,326,020   4,014,771
   Targeted strategy                   1,416,185    2,272,838    2,403,868   6,774,350    2,022,018    4,554,258    4,880,764    1,094,184
  DALY averted                                                                                                                   
   Universal strategy                  35           206          78          3,508        278          1,499        1,533        292
   Targeted strategy                   17           101          38          1,719        136          735          751          143
  ACER                                                                                                                           
   Universal strategy                  299,952      111,957      116,948     11,140       61,671       22,330       21,087       13,749
   Targeted strategy                   83,305       22,503       63,260      3,941        14,868       6,196        6,499        7,652
  Reference (3 times GDP per capita)   10,771       10,838       13,737      28,440       32,095       17,052       23,855       49,933
  ICER                                                                                                                           
   Universal strategy                  504,564      198,003      167,951     18,057       106,497      37,851       35,096       19,601
   Targeted strategy                   83,305       22,503       63,260      3,941        14,868       6,196        6,499        7,652

Multivariate sensitivity analyses were performed for transition probability parameters to determine the robustness of the model. The results suggested the variables whose range of uncertainty had a great impact on the cost-effectiveness of the screening strategies were the program coverage, diagnosis rate, and intervention rate. Figure [3](#F3){ref-type="fig"} showed that the increasing proportion of the benefit population, which was estimated by multiplying the three variables, reduced ACER of different strategies and gradually helped both reach better cost-effectiveness. Targeted strategy trended to be cost-effective in Guangxi, Jiangxi, Henan, Guangdong, Zhejiang, Hebei, Shandong, and Beijing from the level of 9%, 9%, 8%, 4%, 3%, 7%, 5%, and 2%, respectively; while universal strategy trended to be cost-effective in those provinces from the level of 70%, 70%, 48%, 10%, 8%, 28%, 15%, 4%, respectively.

![**The relationship of the average cost-effectiveness ratio (ACER) and the proportion of benefit population for two screening strategies (universal screening and targeted screening)**.](1472-6963-12-97-3){#F3}

Economic effects on long-term costs saving
------------------------------------------

Costs would be saved if early detection and intervention was given. In our model, universal strategy and targeted strategy led to 214,024,820 and 104,872,740 Int\$ of long-term costs saving in total which are approximately equivalent to 0.14% and 0.07% of the annual health expenditure \[[@B36]\].

At the baseline, both strategies achieve cost savings which were greater than implementation costs. When the proportion of benefit population expanded, the effect of these screening strategies on the long-term costs saving become more and more significant, especially those of universal strategies, exceeding the total costs of the screening program implementation, suggesting a good economic effect in the long term (Figure [4](#F4){ref-type="fig"}).

![**The relationship of the long-term costs saving or implementation costs of two screening strategies (universal screening and targeted screening) and the proportion of benefit population**.](1472-6963-12-97-4){#F4}

Discussion
==========

WHO has recommended the implementation of NHS program in member states, particularly in developing countries, based on the experiences and contributions of leading experts from various world regions and across relevant disciplines \[[@B45]\]. This study found there was a huge disparity in the implementation of the NHS program in the surveyed provinces. In general, those developed provinces had much higher program coverage, diagnosis rates and intervention rates, leading to a larger benefit population and helping the NHS program achieve better cost-effectiveness. In fact, the NHS program had been adopted several years in some developed provinces in China with financial and administrative supports by local health government \[[@B46]\]. Under the decentralization of health financing, the developed provinces have a stronger financial capacity to invest in health programs \[[@B47]\]. This difference in implementation and in underlying financial factors has also been reflected in the national plan. Regarding the accessibility of the screening, diagnosis and intervention services, the short-term goal is to achieve a coverage rate of 80% in the eastern provinces (the most developed region of China), 40% in the moderate provinces, and 30% in the western provinces (the least developed region of China) by 2012, and to increase these figures to 90%, 60% and 50%, respectively, by 2015 \[[@B17]\].

Can the national plan help the NHS program achieve its goal with good cost-effectiveness, health and long-term economic effects, at both the national and the regional level? The goal of the NHS program in China is to establish a nationwide hospital-based universal program and to continuously expand diagnosis and intervention services \[[@B17]\]. The rationale for implementing a universal strategy is that it can detect more deaf infants, providing a greater opportunity for them to experience normal language development, while also providing overall benefits in terms of the reduction in disability and the improvement in health and well-being of the Chinese population. As the program\'s implementation varies by different socioeconomic development status, a sufficiently high coverage rate, diagnosis rate and intervention rate ensure that the universal strategy achieves good cost-effectiveness and the relevant health and economic effects in Beijing, Shandong and Hebei; but in the other three provinces Henan, Jiangxi and Guangxi, where these three indicators were low, targeted strategies tend to be more feasible, similar to previous policy suggestions that have been advanced in relation to developing countries \[[@B20],[@B48]\]. Meanwhile, a pilot survey on context-specific risk factors for PCEHI in diverse settings should be implemented to facilitate the targeted strategy.

The study also attempted to estimate the long-term economic effect of the NHS program in China. As the available data and evidence is limited and this is a very preliminary approach, only costs saving in rehabilitation and special education up to 15 years of age (at which children finish their compulsory education) were counted, potentially leading to an underestimate of the economic effect. Even so, the results showed that at the baseline, the costs saved already exceeded the implementation costs in the targeted strategies; as the proportion of the benefit population expends, the economic effect would be more and more significant, especially in relation to universal strategies. Such results strongly support the implementation of the NHS program and suggest potentially greater benefits of adopting universal strategies in China.

Our study was restricted by the limited availability of data and evidence. First, globally, there was no strong evidence based on randomized controlled trials for the effectiveness of NHS on deaf infants\' language development, and consequently, no evidence as regards the evaluation of their psychological and educational-related outcomes. The impact of early intervention on long-term cost saving remains unknown. Moreover, in China, there has been no previous nationwide population-based study to survey the epidemiological status of PCEHI. Data on the prevalence used in this study were therefore derived from a crude estimation based on the number of the hearing disabled population and a few regional surveys. All that needs to be researched in future. Last, due to the unavailability of child-onset disability weights for hearing loss, we attempted to use adult-onset disability weights instead into the economic evaluation. It may underestimate the health effects of NHS as early detection and intervention leads to much more benefits on children\'s language development.

Conclusions
===========

In conclusion, universal strategy can be considered as the ultimate implementation goal as it provides the best health and economic effects. A universal strategy is feasible in provinces where screening, diagnosis and intervention services are good enough to benefit sufficient proportion of the deaf children. In the other regions, a targeted strategy is temporarily more realistic than a universal strategy; however, related services still need to be scaled up to cover the targeted population as much as possible. The reference data from this study thus are expected to be of particular benefit in terms of the \'rolling out\' of the national plan.
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